ARC
EPZM

Absolute Return Capital’s Epizyme, Inc EPZM Stock Holding History

Absolute Return Capital’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-4,108
Closed -$128K – 1015
2014
Q2 		$128K Buy
+4,108
New +$96.7K ﹤0.01% 1089

Other funds holding EPZM

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Absolute Return Capital's EPZM Position: Q3 2014 in Review

Absolute Return Capital sold out of Epizyme, Inc (EPZM) in Q3 2014, closing a stake of 4,108 shares — an estimated $128K sold.

Absolute Return Capital first reported a position in EPZM in Q2 2014 and held it in 1 quarter. The position peaked at $128K in Q2 2014. 94 funds tracked by Wall St. Rank hold EPZM as of Q3 2014.

  • Absolute Return Capital reported no remaining Epizyme, Inc position as of Q3 2014 after selling out during the quarter.
  • Absolute Return Capital sold 4,108 Epizyme, Inc shares in Q3 2014, an estimated $128K.
  • Absolute Return Capital first reported a position in Epizyme, Inc in Q2 2014 and held it in 1 quarter.
  • Absolute Return Capital's Epizyme, Inc position peaked at $128K in Q2 2014.
  • 94 funds tracked by Wall St. Rank held Epizyme, Inc as of Q3 2014.

Based on Absolute Return Capital's 13F filing for Q3 2014, filed 14 Nov 2014.